Advanced search
Publication Cover
Therapeutic Delivery Volume 2, 2011 - Issue 10
Submit an article Journal homepage
163
Views
0
CrossRef citations to date
0
Altmetric
Review

Trans-scleral Delivery of Macromolecules

Silvia Pescina1 Department of Pharmacy University of ParmaParco Area delle Scienze 27/AParma43124Italy
,
Patrizia Santi1 Department of Pharmacy University of ParmaParco Area delle Scienze 27/AParma43124Italy
,
Giulio Ferrari2 Bietti Eye FoundationVia Livenza 3Roma00198Italy
&
Sara Nicoli1 Department of Pharmacy University of ParmaParco Area delle Scienze 27/AParma43124Italy;3 [email protected]
Pages 1331-1349 | Published online: 13 Oct 2011

Bibliography

  • Resnikoff S , PascoliniD, Etya‘aleDet al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844–851 (2004).
  • Sampat KM , GargSJ. Complications of intravitreal injections. Curr. Opin. Ophthalmol.21, 178–183 (2010).
  • Jiang C , MooreMJ, ZhangX, KlassenH, LangerR, YoungM. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis.13, 1783–1792 (2007).
  • Bourges JL , BloquelC. Thomas A et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Delivery Rev.58, 1182–1202 (2006).
  • Choonara YE , PillayV, DanckwertsMP, CarmichaelTR, du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J. Pharm. Sci.99, 2219–2239 (2010).
  • Ranta VP , UrttiA. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev.58, 1164–1181 (2006).
  • Raghava S , HammondM, KompellaUB. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv.1, 99–114 (2004).
  • Thrimawithana TR , YoungS, BuntCR, GreenC, AlanyRG. Drug delivery to the posterior segment of the eye. Drug Discov. Today16, 270–277 (2011).
  • Del Amo EM , UrttiA. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today13, 135–143 (2008).
  • Eljarrat-Binstock E , Pe‘erJ, DombAJ. New techniques for drug delivery to the posterior eye segment. Pharm. Res.27, 530–543 (2010).
  • Gaudana R , AnanthulaHK, ParenkyA, MitraAK. Ocular drug delivery. AAPS J.12, 348–360 (2010).
  • Kuppermann BD , LoewensteinA. Drug delivery to the posterior segment of the eye. Dev. Ophthalmol.47, 59–72 (2010).
  • Kearns VR , WilliamsRL. Drug delivery systems for the eye. Expert Rev. Med. Devices6, 277–290 (2009).
  • Barocas VH , BalachandranRK. Sustained transscleral drug delivery. Expert Opin. Drug Deliv.5, 1–10 (2008).
  • Kim SH , LutzRJ, WangNS, RobinsonMR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res.39, 244–254 (2007).
  • Anderson OA , BainbridgeJW, ShimaDT. Delivery of anti-angiogenic molecular therapies for retinal disease. Drug Discov. Today15, 272–282 (2010).
  • Lambiase A , AloeL, CentofantiMet al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc. Natl Acad. Sci. USA 106, 13469–13474 (2009).
  • Zhang K , HopkinsJJ, HeierJSet al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc. Natl Acad. Sci. USA 108, 6241–6245 (2011).
  • El Sanharawi M , KowalczukL, TouchardE, OmriS, de Kozak Y, Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog. Retinal Eye Res.29, 443–465 (2010).
  • Fattal E , BochotA. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev.58, 1203–1223 (2006).
  • Mandel M . Some Properties of Polyelectrolyte Solutions and the Scaling Approach. Marcel Dekker, NY, USA (1993).
  • Wang L , YuH. Chain conformation of linear polyelectrolyte in salt solutions: sodium poly(styrene sulfonate) in potassium chloride and sodium chloride solutions. Macromolecules21, 3498–3501 (1988).
  • Boswell CA , TesarDB, MukhyalaK, TheilFP, FielderPJ, KhawliLA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug. Chem.21(12), 2153–2163 (2010).
  • Hayakawa E , ChienDS, InagakiK, YamamotoA, WangW, LeeVH. Conjunctival penetration of insulin and peptide drugs in the albino rabbit. Pharm. Res.9, 769–775 (1992).
  • Hosoya K , LeeVH, KimKJ. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur. J. Pharm. Biopharm.60, 227–240 (2005).
  • Sasaki H , YamamuraK, MukaiTet al. Modification of ocular permeability of peptide drugs by absorption promoters. Biol. Pharm. Bull. 23, 1524–1527 (2000).
  • Sasaki H , YamamuraK, TeiC, NishidaK, NakamuraJ. Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. J. Drug Target.3, 129–135 (1995).
  • Horibe Y , HosoyaK, KimKJ, OgisoT, LeeVH. Polar solute transport across the pigmented rabbit conjunctiva: size dependence and the influence of 8-bromo cyclic adenosine monophosphate. Pharm. Res.14, 1246–1251 (1997).
  • Nomoto H , ShiragaF, KunoNet al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 50, 4807–4813 (2009).
  • Hagigit T , AbdulrazikM, OrucovFet al. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J. Control. Release 145, 297–305 (2010).
  • Furrer E , BerdugoM, StellaCet al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-α single-chain antibody, upon topical administration to the rabbit eye. Invest. Ophthalmol. Vis. Sci. 50, 771–778 (2009).
  • Ottiger M , ThielMA, FeigeU, LichtlenP, UrechDM. Efficient intraocular penetration of topical anti-TNF-α single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest. Ophthalmol. Vis. Sci.50, 779–786 (2009).
  • Ahmed I , PattonTF. Importance of the noncorneal absorption route in topical ophthalmic drug deliveryInvest. Ophthalmol. Vis. Sci.26, 584–587 (1985).
  • Kim TW , LindseyJD, AiharaM, AnthonyTL, WeinrebRN. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci.43, 1809–1816 (2002).
  • Li J , WasmuthS, BauerD, BaehlerH, HennigM, HeiligenhausA. Subconjunctival antisense oligonucleotides targeting TNF-α influence immunopathology and viral replication in murine HSV-1 retinitis. Graefes Arch. Clin. Exp. Ophthalmol.246, 1265–1273 (2008).
  • Gehlbach P , DemetriadesAM, YamamotoSet al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. 10, 637–646 (2003).
  • Kim SH , CsakyKG, WangNS, LutzRJ. Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm. Res.25, 512–520 (2008).
  • Edwards A , PrausnitzMR. Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. AIChE J.44, 214–225 (1998).
  • Boubriak OA , UrbanJP, AkhtarS, MeekKM, BronAJ. The effect of hydration and matrix composition on solute diffusion in rabbit sclera. Exp. Eye Res.71, 503–514 (2000).
  • Maurice DM , PolgarJ. Diffusion across the sclera. Exp. Eye Res.25, 577–582 (1977).
  • Olsen TW , EdelhauserHF, LimJI, GeroskiDH. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci.36, 1893–1903 (1995).
  • Ambati J , CanakisCS, MillerJWet al. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 41, 1181–1185 (2000).
  • Kadam RS , CheruvuNP, EdelhauserHF, KompellaUB. Sclera–choroid–RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models. Invest. Ophthalmol. Vis. Sci.52(8), 5387–5399 (2011).
  • Nicoli S , FerrariG, QuartaMet al. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability. Mol. Vis. 15, 259–266 (2009).
  • Prausnitz MR , NoonanJS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci.87, 1479–1488 (1998).
  • Macchioni A , CiancaleoniG, ZuccacciaC, ZuccacciaD. Determining accurate molecular sizes in solution through NMR diffusion spectroscopy. Chem. Soc. Rev.37, 479–489 (2008).
  • Wen H , HaoJ, LiSK. Influence of permeant lipophilicity on permeation across human sclera. Pharm. Res.27, 2446–2456 (2010).
  • Kadam RS , KompellaUB. Influence of lipophilicity on drug partitioning into sclera, choroid–retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J. Pharmacol. Exp. Ther.332, 1107–1120 (2010).
  • Thakur A , KadamRS, KompellaUB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab. Dispos.39, 771–781 (2011).
  • Cheruvu NP , KompellaUB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid–Bruch‘s layer. Invest. Ophthalmol. Vis. Sci.47, 4513–4522 (2006).
  • Lin CW , WangY, ChallaP, EpsteinDL, YuanF. Transscleral diffusion of ethacrynic acid and sodium fluorescein. Mol. Vis.13, 243–251 (2007).
  • Ranta VP , MannermaaE, LummepuroKet al. Barrier analysis of periocular drug delivery to the posterior segment. J. Control. Release 148(1), 42–48 (2010).
  • Gyenge CC , TenstadO, WiigH. In vivo determination of steric and electrostatic exclusion of albumin in rat skin and skeletal muscle. J. Physiol.552, 907–916 (2003).
  • Taylor AE , ParkerJC. Intersitial exluded volumes: the effect of charge. J. Physiol.553, 333 (2003).
  • Carrasquillo KG , RickerJA, RigasIK, MillerJW, GragoudasES, AdamisAP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci.44, 290–299 (2003).
  • Alberdi E , HydeCC, BecerraSP. Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site. Biochemistry37, 10643–10652 (1998).
  • Waldbillig RJ , ArnoldDR, FletcherRT, ChaderGJ. Insulin and IGF-1 binding in chick sclera. Invest. Ophthalmol. Vis. Sci.31, 1015–1022 (1990).
  • Hussain AA , StaritaC, HodgettsA, MarshallJ. Macromolecular diffusion characteristics of ageing human Bruch‘s membrane: implications for age-related macular degeneration (AMD). Exp. Eye Res.90, 703–710 (2010).
  • Bernstein MH , HollenbergMJ. Fine structure of the choriocapillaris and retinal capillaries. Invest. Ophthalmol. Vis. Sci.4, 1016–1025 (1965).
  • Starita C , HussainAA, PatmoreA, MarshallJ. Localization of the site of major resistance to fluid transport in Bruch‘s membrane. Invest. Ophthalmol. Vis. Sci.38, 762–767 (1997).
  • Moore DJ , CloverGM. The effect of age on the macromolecular permeability of human Bruch‘s membrane. Invest. Ophthalmol. Vis. Sci.42, 2970–2975 (2001).
  • Pitkanen L , RantaVP, MoilanenH, UrttiA. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci.46, 641–646 (2005).
  • Pescina S , PadulaC, SantiP, NicoliS. Effect of formulation factors on the trans-scleral iontophoretic and post-iontophoretic transport of a 40 kDa dextran in-vitro. Eur. J. Pharm. Sci.42, 503–508 (2011).
  • Amrite A , PugazhenthiV, CheruvuN, KompellaU. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert. Opin. Drug Deliv.7, 631–645 (2010).
  • Cheruvu NP , AmriteAC, KompellaUB. Effect of eye pigmentation on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci.49, 333–341 (2008).
  • Pitkanen L , RantaVP, MoilanenH, UrttiA. Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid–retinal pigment epithelium. Pharm. Res.24, 2063–2070 (2007).
  • Geng J , YuanP, ShaoCet al. Bacterial melanin interacts with double-stranded DNA with high affinity and may inhibit cell metabolism in vivo. Arch. Microbiol. 192, 321–329 (2010).
  • Eckhart L , BachJ, BanJ, TschachlerE. Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem. Biophys. Res. Commun.271, 726–730 (2000).
  • Chan JE , PridgenTA, CsakyKG. Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon‘s implant in the rat. Exp. Eye Res.90, 501–506 (2010).
  • Robinson MR , LeeSS, KimHet al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 82, 479–487 (2006).
  • Spitznas M , RealeE. Fracture faces of fenestrations and junctions of endothelial cells in human choroidal vessels. Invest. Ophthalmol. Vis. Sci.14, 98–107 (1975).
  • Rieke ER , AmaralJ, BecerraSP, LutzRJ. Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J. Ocul. Pharmacol. Ther.26, 55–64 (2010).
  • Steuer H , JaworskiA, StollD, SchlosshauerB. In vitro model of the outer blood–retina barrier. Brain Res. Brain Res. Protoc.13, 26–36 (2004).
  • Hornof M , ToropainenE, UrttiA. Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm.60, 207–225 (2005).
  • Mannermaa E , ReinisaloM, RantaVPet al. Filter-cultured ARPE-19 cells as outer blood–retinal barrier model. Eur. J. Pharm. Sci. 40, 289–296 (2010).
  • Mannermaa E , VellonenKS, RyhanenTet al. Efflux protein expression in human retinal pigment epithelium cell lines. Pharm. Res. 26, 1785–1791 (2009).
  • Mannermaa E , VellonenKS, UrttiA. Drug transport in corneal epithelium and blood–retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev.58, 1136–1163 (2006).
  • Amaral J , FarissRN, CamposMMet al. Transscleral–RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. Invest. Ophthalmol. Vis. Sci. 46, 4383–4392 (2005).
  • Mac Gabhann F , DemetriadesAM, DeeringTet al. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann. Biomed. Eng. 35, 615–630 (2007).
  • Ban Y , RizzoloLJ. A culture model of development reveals multiple properties of RPE tight junctions. Mol. Vis.3, 18 (1997).
  • Anderson OA , JacksonTL, SinghJK, HussainAA, MarshallJ. Human transscleral albumin permeability and the effect of topographical location and donor age. Invest. Ophthalmol. Vis. Sci.49, 4041–4045 (2008).
  • Chiang A , HallerJA. Vitreoretinal disease in the coming decade. Curr. Opin. Ophthalmol.21, 197–202 (2010).
  • Conway BR . Recent patents on ocular drug delivery systems. Recent Pat. Drug Deliv. Formul.2, 1–8 (2008).
  • Srivastava R , PathakK. An updated patent review on ocular drug delivery systems with potential for commercial viability. Recent Pat. Drug Deliv. Formul.5, 146–162 (2011).
  • Diebold Y , CalongeM. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res.29, 596–609 (2010).
  • Bochot A , LajavardiL, CameloSet al. Potential of liposomes for the intravitreal injection of therapeutic molecules. Ann. Pharm. Fr. 69, 100–107 (2011).
  • Tamboli V , MishraGP, MitraAK. Polymeric vectors for ocular gene delivery. Therapeutic Delivery2, 523–536 (2011).
  • Kompella UB , KadamRS, LeeVH. Recent advances in ophthalmic drug delivery. Therapeutic Delivery1, 435–456 (2010).
  • Hironaka K , InokuchiY, TozukaY, ShimazawaM, HaraH, TakeuchiH. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J. Control. Release136, 247–253 (2009).
  • Tsui JY , DalgardC, Van Quill KR et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest. Ophthalmol. Vis. Sci.49, 490–496 (2008).
  • Simpson AE , GilbertJA, RudnickDEet al. Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch. Ophthalmol. 120, 1069–1074 (2002).
  • Van Quill KR , DioguardiPK, TongCTet al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112, 1151–1158 (2005).
  • Amrite AC , KompellaUB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol.57, 1555–1563 (2005).
  • Kang Derwent JJ , MielerWF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans. Am. Ophthalmol. Soc.106, 206–213; discussion 213–214 (2008).
  • Misra GP , SinghRS, AlemanTS, JacobsonSG, GardnerTW, LoweTL. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials30, 6541–6547 (2009).
  • Ambati J , GragoudasES, MillerJWet al. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41, 1186–1191 (2000).
  • Kawashima T , NagaiN, KajiHet al. A scalable controlled-release device for transscleral drug delivery to the retina. Biomaterials 32, 1950–1956 (2011).
  • Jorgensen L , NielsonHM. Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines. John Wiley & Sons Ltd, Chichester, UK (2010).
  • Jiang J , GillHS, GhateDet al. Coated microneedles for drug delivery to the eye. Invest. Ophthalmol. Vis. Sci. 48, 4038–4043 (2007).
  • Jiang J , MooreJS, EdelhauserHF, PrausnitzMR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm. Res.26, 395–403 (2009).
  • Patel SR , LinAS, EdelhauserHF, PrausnitzMR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res.28, 166–176 (2011).
  • Mitragotri S , KostJ. Low-frequency sonophoresis: a noninvasive method of drug delivery and diagnostics. Biotechnol. Prog.16, 488–492 (2000).
  • Lavon I , KostJ. Ultrasound and transdermal drug delivery. Drug Discov. Today9, 670–676 (2004).
  • Cheung AC , YuY, TayD, WongHS, Ellis-BehnkeR, ChauY. Ultrasound-enhanced intrascleral delivery of protein. Int. J. Pharm.401, 16–24 (2010).
  • Luzardo-Alvarez A , Rodriguez-FernandezM, Blanco-MendezJ, GuyRH, Delgado-CharroMB. Iontophoretic permselectivity of mammalian skin: characterization of hairless mouse and porcine membrane models. Pharm. Res.15, 984–987 (1998).
  • Fisher GA , ParkinsonTM, SzlekMA. Ocuphor – the future of ocular drug delivery. Drug Deliv. Tech.2, 50–52 (2002).
  • Parkinson TM , FergusonE, FebbraroS, BakhtyariA, KingM, MundasadM. Tolerance of ocular iontophoresis in healthy volunteers. J. Ocul. Pharmacol. Ther.19, 145–151 (2003).
  • Vollmer DL , SzlekMA, KolbK, LloydLB, ParkinsonTM. In vivo transscleral iontophoresis of amikacin to rabbit eyes. J. Ocul. Pharmacol. Ther.18, 549–558 (2002).
  • Eljarrat-Binstock E , DombAJ, OrucovF, DaganA, Frucht-PeryJ, Pe‘erJ. In vitro and in vivo evaluation of carboplatin delivery to the eye using hydrogel-iontophoresis. Curr. Eye Res.33, 269–275 (2008).
  • Eljarrat-Binstock E , DombAJ, OrucovF, Frucht-PeryJ, Pe‘erJ. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr. Eye Res.32, 639–646 (2007).
  • Gungor S , Delgado-CharroMB, Ruiz-PerezBet al. Trans-scleral iontophoretic delivery of low molecular weight therapeutics. J. Control. Release 147, 225–231 (2010).
  • Behar-Cohen FF , El Aouni A et al. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp. Eye Res.74, 51–59 (2002).
  • Voigt M , KralingerM, KieselbachGet al. Ocular aspirin distribution: a comparison of intravenous, topical and Coulomb-controlled iontophoresis administration. Invest. Ophthalmol. Vis. Sci. 43, 3299–3306 (2002).
  • Nicoli S , FerrariG, QuartaM, MacalusoC, SantiP. In vitro transscleral iontophoresis of high molecular weight neutral compounds. Eur. J. Pharm. Sci.36, 486–492 (2009).
  • Chopra P , HaoJ, LiSK. Iontophoretic transport of charged macromolecules across human sclera. Int. J. Pharm.388, 107–113 (2010).
  • Pescina S , FerrariG, GovoniP, MacalusoCet al. In vitro permeation of bevacizumab through human sclera: effect of iontophoresis application. J. Pharm. Pharmacol.62, 1189–1194 (2010).
  • Davies JB , CiavattaVT, BoatrightJH, NickersonJM. Delivery of several forms of DNA, DNA–RNA hybrids, and dyes across human sclera by electrical fields. Mol. Vis.15, 569–578 (2003).
  • Asahara T , ShinomiyaK, NaitoT, ShiotaH. Induction of gene into the rabbit eye by iontophoresis: preliminary report. Jpn J. Ophthalmol.45, 31–39 (2001).
  • Voigt M , de Kozak Y, Halhal M, Courtois Y, Behar-Cohen F. Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem. Biophys. Res. Commun.295, 336–341 (2002).
  • Souied EH , ReidSNM, PiriNI, LernerLE, NusinowitzS, FarberDB. Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration. Exp. Eye Res.87, 168–175 (2008).
  • Molokhia SA , JeongEK, HiguchiWI, LiSK. Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp. Eye Res.88, 418–425 (2009).
  • Amrite AC , EdelhauserHF, KompellaUB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest. Ophthalmol. Vis. Sci.49, 320–332 (2008).
  • Balachandran RK , BarocasVH. Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow. Pharm. Res.25, 2685–2696 (2008).
  • Lee TW , RobinsonJR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J. Ocul. Pharmacol. Ther.20, 43–53 (2004).
  • Lee TW , RobinsonJR. Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection. J. Ocul. Pharmacol. Ther.25, 29–37 (2009).
  • Mac Gabhann F , DemetriadesAM, DeeringTet al. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann. Biomed. Eng. 35, 615–630 (2007).
  • Dias CS , MitraAK. Vitreal elimination kinetics of large molecular weight FITC-labeled dextrans in albino rabbits using a novel microsampling technique. J. Pharm. Sci.89, 572–578 (2000).
  • Durairaj C , ShahJC, SenapatiS, KompellaUB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure–pharmacokinetic relationships (QSPKR). Pharm. Res.26, 1236–1260 (2009).
  • Cruysberg LP , NuijtsRM, GeroskiDH, GilbertJA, HendrikseF, EdelhauserHF. The influence of intraocular pressure on the transscleral diffusion of high-molecular-weight compounds. Invest. Ophthalmol. Vis. Sci.46, 3790–3794 (2005).
  • Shuler RK Jr, Dioguardi PK, Henjy C, Nickerson JM, Cruysberg LP, Edelhauser HF. Scleral permeability of a small, single-stranded oligonucleotide. J. Ocul. Pharmacol. Ther.20, 159–168 (2004).
  • Ethier CR , JohnsonM, RubertiJ. Ocular biomechanics and biotransport. Annu. Rev. Biomed. Eng.6, 249–273 (2004).
  • Ahmed I , GokhaleRD, ShahMV, PattonTF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci.76, 583–586 (1987).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.